Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $42.2 million.

  • UroGen Pharma's Shares Outstanding (Weighted Average) rose 9.85% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year increase of 9.85%. This contributed to the annual value of $42.2 million for FY2024, which is 36.72% up from last year.
  • Latest data reveals that UroGen Pharma reported Shares Outstanding (Weighted Average) of $42.2 million as of FY2024, which was up 36.72% from $30.9 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Shares Outstanding (Weighted Average) registered a high of $42.2 million during FY2024, and its lowest value of $22.1 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $32.1 million, with a median of $30.9 million in 2023.
  • Data for UroGen Pharma's Shares Outstanding (Weighted Average) shows a peak YoY soared of 36.72% (in 2024) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Shares Outstanding (Weighted Average) (Yearly) stood at $22.1 million in 2020, then climbed by 1.48% to $22.4 million in 2021, then climbed by 2.99% to $23.1 million in 2022, then skyrocketed by 33.68% to $30.9 million in 2023, then skyrocketed by 36.72% to $42.2 million in 2024.